# The Complementary Use of Both $\beta3$ Agonists Could Play a Key Role in Optimizing OAB Management

Naoki Wada, Taichiro Ishimaru, Kotona Miyauchi, Noriyuki Abe, Daiki Kikuchi, Miyu Ohtani

Department of Renal and Urologic Surgery, Asahikawa Medical University, Asahikawa, Japan

# Drug utilization and persistence rate of mirabegron and vibegron for overactive bladder

# **Background**

In our previous research, we reported relatively favorable long-term persistence with mirabegron at our institution before the introduction of vibegron (61-66% at 12 months) (Int J Urol 2018). We aimed to assess the real-world usage and persistence rates of mirabegron and vibegron in patients with OAB.

### Methods


This retrospective study reviewed patients who were prescribed either mirabegron or vibegron as their initial treatment for OAB between Aug. 2022 and Dec. 2023.


Data collected included patient demographics (sex, age), pre-existing conditions, treatment duration, drug discontinuation, reasons for discontinuation, and subsequent drug changes if therapy was discontinued due to adverse events (AEs) or lack of efficacy.


Persistence was analyzed in two phases: First, for mirabegron and vibegron individually (*Persistence Rate I*). Second overall β3 agonist use in patients who switched between the two drugs (*Persistence Rate II*).

## Results


	1	1irabegron	Vibegror	P value
No.	9	94 (73%)	34 (27%)	)
Gender, n (%)	ale	59 (63%)	13 (38%)	
Fema	ale	35 (37%)	21 (62%)	0.01
Median age (years)		69.5	68.3	0.62
Underlying neurogenic diseases, n (%)	1	9 (20%)	8 (24%)	0.46
Prostatic volume (only in male)		34.9 ml	29.8 ml	0.52
OABSS	7.	.7 (n=29)	9.1 (n=20	0.10
No. discontinuation, n (%)	5	55 (59%)	14 (41%)	0.08
Median continuation period (months)		8.9	10.6	0.31








# Persistence rate II





# Interpretation

The availability of another  $\beta 3$  agonist allows sequential mirabegron-to-vibegron therapy, that may influence the persistence rate of these drugs. The availability of two  $\beta 3$  agonists may facilitate treatment switching and support long-term adherence of  $\beta 3$  agonists .